Figure 6.
Figure 6. Effect of SB203580 (p38MAPKi), PD98059 (P42/44ERKi), LY294002 (PI3Ki), and herbimycin A inhibitors on LAG-3–induced down-regulation of antigen uptake by human monocyte-derived dendritic cells. Immature DCs were treated for 24 hours with 10 μg/mL IgG1 or LAG-3Ig after preincubation with each inhibitor for 2 hours as indicated. Cells were then incubated with BSA-FITC for 30 minutes at 4°C or 37°C, and the BSA uptake was determined by FACS analysis. The percentage of FITC-positive cells was used to calculate the percentage of inhibition of LAG-3–induced down-regulation of BSA uptake by the indicated inhibitors. As the inhibitors were dissolved in DMSO, cells treated with the same concentration of DMSO alone (0.1%) were used as a control. Data are given as mean ± SEM of at least 3 independent experiments.

Effect of SB203580 (p38MAPKi), PD98059 (P42/44ERKi), LY294002 (PI3Ki), and herbimycin A inhibitors on LAG-3–induced down-regulation of antigen uptake by human monocyte-derived dendritic cells. Immature DCs were treated for 24 hours with 10 μg/mL IgG1 or LAG-3Ig after preincubation with each inhibitor for 2 hours as indicated. Cells were then incubated with BSA-FITC for 30 minutes at 4°C or 37°C, and the BSA uptake was determined by FACS analysis. The percentage of FITC-positive cells was used to calculate the percentage of inhibition of LAG-3–induced down-regulation of BSA uptake by the indicated inhibitors. As the inhibitors were dissolved in DMSO, cells treated with the same concentration of DMSO alone (0.1%) were used as a control. Data are given as mean ± SEM of at least 3 independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal